Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)
Figure 2
Correlation between augmented-specific tetramer responses and serum PSA status. The average tetramer measurements at week 26 minus prevaccine levels (Δ26) inversely correlated with lower risk of serum PSA progression at six months following the onset of immunotherapy (). “NP” denotes stable biochemical disease or nonprogression, while “P” denotes biochemical progression.
